



Exploratory efficacy endpoints. Patients receiving vocacapsaicin 0.30 mg/mL had reduced pain over 2 weeks (panel A, $p = 0.011$), consumed less opioid over 2 weeks (panel B, $p = 0.001$), had less pain at rest from day 4 through day 14 (panel C, $p = 0.028$), and had reduced opioid requirement from day 4 through day 14 (panel D, $p = 0.035$). Vocacapsaicin 0.30 mg/mL reduced pain with ambulation over the first week (panel E, $p = 0.012$) and over 2 weeks (panel F, $p = 0.028$).